ImmuCell Corporation (ICCC)vsRevolution Medicines Inc (RVMD)
ICCC
ImmuCell Corporation
$10.13
+1.81%
HEALTHCARE · Cap: $87.01M
RVMD
Revolution Medicines Inc
$192.76
+0.95%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
ImmuCell Corporation generates 4034% more annual revenue ($30.68M vs $742,000). ICCC leads profitability with a 2.6% profit margin vs 0.0%. ICCC earns a higher WallStSmart Score of 47/100 (D+).
ICCC
Hold47
out of 100
Grade: D+
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.5%
Fair Value
$17.78
Current Price
$10.13
$7.65 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 259.9% YoY
Reasonable price relative to book value
Strong operational efficiency at 26.9%
Conservative balance sheet, low leverage
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
2.6% margin — thin
Premium valuation, high expectations priced in
Trading at 15.9x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ICCC
The strongest argument for ICCC centers on EPS Growth, Price/Book, Operating Margin. Revenue growth of 11.5% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : ICCC
The primary concerns for ICCC are Altman Z-Score, Market Cap, Profit Margin. A P/E of 136.9x leaves little room for execution misses. Thin 2.6% margins leave little buffer for downturns.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
ICCC is growing revenue faster at 11.5% — sustainability is the question.
ICCC generates stronger free cash flow (2M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ICCC scores higher overall (47/100 vs 24/100) and 11.5% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ImmuCell Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
ImmuCell Corporation, an animal health company, develops, manufactures and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. The company is headquartered in Portland, Maine.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?